NICE to Recommend Kadcyla, Kyprolis for NHS Funding; But Rejects Besponsa Coverage Before EU Approval

The U.K. is planning to move Roche’s Kadcyla (trastuzumab emtansine) into the NHS’s routine funding programs later this summer, following guidance from the National Institute for Health and Care Excellence…

Continue ReadingNICE to Recommend Kadcyla, Kyprolis for NHS Funding; But Rejects Besponsa Coverage Before EU Approval

Epizyme Falls as Investors Take in Disappointing Phase II Data

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks2.jpg" NAME"Epizyme Falls as Investors Take in Disappointing Phase II Data" ALT"Epizyme Falls as Investors Take in Disappointing Phase II Data"June 15, 2017By Alex Keown, BioSpace.com Breaking News Staff...…

Continue ReadingEpizyme Falls as Investors Take in Disappointing Phase II Data

New Biotech Incubator Just Opened Up in the Big Apple&mdash;With Room for 25 Startups

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-alexandria-launchlabs.jpg" NAME"New Biotech Incubator Just Opened Up in the Big AppleWith Room for 25 Startups" ALT"New Biotech Incubator Just Opened Up in the Big AppleWith Room for 25 Startups"June…

Continue ReadingNew Biotech Incubator Just Opened Up in the Big Apple&mdash;With Room for 25 Startups

UK Charity to Use $638 Million Cash From Merck & Co.'s Blockbuster Keytruda to Back R&D

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-scientist5.jpg" NAME"UK Charity to Use $638 Million Cash From Merck & Co.'s Blockbuster Keytruda to Back R&D" ALT"UK Charity to Use $638 Million Cash From Merck & Co.'s Blockbuster…

Continue ReadingUK Charity to Use $638 Million Cash From Merck & Co.'s Blockbuster Keytruda to Back R&D